Osteopore (ASX: OSX), a regenerative medicine company specialising in bioresorbable implants, has received market approval in Switzerland for its off-the-shelf and custom-made products. Osteopore is focused on developing and commercialising innovative regenerative implants to assist the body’s natural ability to restore bone and tissue. Their technology aims to improve patient outcomes in a range of surgical procedures.
The approval was granted under the European Union’s Medical Device Regulations (MDR) and follows Osteopore’s partnership with Zimmer Biomet, a US orthopaedic solutions company. This partnership focuses on distributing Osteopore’s craniofacial products across Europe, the Middle East, Africa, the Asia-Pacific region, Australia, and New Zealand. The high-value implant range is expected to provide Zimmer Biomet with opportunities to offer advanced implants to the Swiss and broader European markets, complementing its existing range of neurosurgical and craniofacial solutions.
Osteopore’s chief executive officer, Dr Yujing Lim, hailed the market approval as a significant achievement for the company. He noted the company’s readiness to support a coordinated approach to the European market, particularly in Switzerland, alongside Zimmer Biomet. Dr. Lim also acknowledged the work of the regulatory professionals whose efforts secured the market authorisation.
Customised implants represent the largest segment of the European cranial implant market, with analysts projecting growth to US$527.6 million by 2027. The broader customised implant market is anticipated to reach $26.7 billion by 2029, driven by an ageing population and increasing demand for advanced medical devices that improve mobility and reduce recovery times. This approval completes Osteopore’s product portfolio, strengthening its market entry into Switzerland and the broader European region.
